[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506442":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":32,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Sohag University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Tenofovir Disoproxil Fumarate and Entcavir","Regular registration of side effects of the drugs, cause of non-compliance to treatment",[14],{"facility":15,"status":16,"city":17,"state":7,"zip":7,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Sohag University hospitals","RECRUITING","Sohag","Egypt","EG",{"type":21,"coordinates":22},"Point",[23,24],31.69478,26.55695,{"lat":24,"lon":23},[27],{"name":28,"role":29,"phone":30,"phoneExt":7,"email":31},"Magdy M Amin, Professor","CONTACT","0934602963","portal@med.sohag.edu.eg",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Rehab Abdelraof Mohamed","Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B patients in Upper Egypt","100506442","clinical-efficacy-and-safety-of-tenofovir-disoproxil-fumarate-and-entcavir-in-treatment-of-chronic-hepatitis-b-patients-in-upper-egypt-100506442",false,"NCT05874440","Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B Patients in Upper Egypt","Inclusion Criteria:\n\n* Patient with HbsAg positivity for at least 6 months.\n* Patients have HbeAg positive or negative.\n* Patient recived Theryapy with ETV 0.5 or 1 mg\u002Fday or TDF 300 mg\u002Fday.\n* Patients have Regular monitoring every 6 months.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old.\n* Patients co-infected with hepatitis C, hepatitis D.\n* Patients receiving immune suppressive therapy or with history of immunodeficiency","ALL","18 Years",{"count":45,"type":46},100,"ESTIMATED","OBSERVATIONAL","Chronic hepatitis B (CHB) is one of the major causes of chronic liver diseases worldwide. Around 296 million people were living with chronic hepatitis B infection, with 1.5 million new infections each year and more than 820 thousand people die because of hepatitis B virus (HBV) related complications",[50],"Chronic Hepatitis b Patients","UNKNOWN","2023-05-22",{"date":54,"type":55},"2023-05-24","ACTUAL",{"date":57,"type":55},"2023-04-15",{"date":59,"type":46},"2024-04-30",{"name":5,"class":6},1]